01Jul
Novartis and Alcon FCPA Enforcement Action: Lessons Learned (Part III of III)
At the outset, Novartis is “lucky” – the settlement is relatively positive, despite its 2016 SEC enforcement action in China. Given Novartis weak culture of compliance (if anything, a better description may be a culture of non-compliance) and its status as a recidivist, Novartis could have been slammed with a stiffer enforcement action, including assignment of an independent corporate compliance monitor and a higher penalty. ...
By:
Michael Volkov
Source Url: https://www.jdsupra.com/legalnews/novartis-and-alcon-fcpa-enforcement-13538/
Related
On December 20, 2019, the Further Consolidated Appropriations Act, 2020 (the “FCAA”) was signed by...
Read More >
SB 123, just passed by the legislature and signed by Governor Brown, makes several amendments to Ore...
Read More >
The Lackawanna Court of Common Pleas in Pennsylvania held, in a matter of first impression, that lan...
Read More >
The German Ministry for Economic Affairs and Energy has published the draft bill on the 10th amendme...
Read More >
Under a California law that took effect on January 1, 2020, employers will have to provide extra not...
Read More >
Depending on a tech start-up company’s initial financial condition, many tech start-ups are sometim...
Read More >